JPRN-jRCT2080223478已完成1 期
Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-Randomized Intervention Model: Parallel Assignment Masking: No masking Primary Purpose: Treatment
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Must have received and progressed on or failed one standard/approved treatment for cancer type, if available
- •At least 4 weeks since any previous treatment for cancer
- •Subject must consent to pretreatment and on treatment tumor biopsies
- •At least one lesion with measurable disease at baseline
排除标准
- •Patients with primary brain tumors or primary tumors with central nervous system metastases as only location of disease. Controlled brain metastases are permitted
- •Prior organ transplant
- •Participants with second/other active cancers requiring current treatment
- •Uncontrolled/significant heart disease
- •History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)
- •Active/uncontrolled autoimmune disease
- •Active infection
研究者
相似试验
进行中（未招募）
1 期
Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors.EUCTR2017-000597-11-PLBristol-Myers Squibb International Corporation600
进行中（未招募）
1 期
Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors.EUCTR2017-000597-11-ROBristol-Myers Squibb International Corporation600
进行中（未招募）
1 期
Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors.Advanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2017-000597-11-NLBristol-Myers Squibb International Corporation600
进行中（未招募）
1 期
Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors.Advanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2017-000597-11-NOBristol-Myers Squibb International Corporation600
进行中（未招募）
1 期
Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors.EUCTR2017-000597-11-FIBristol-Myers Squibb International Corporation600